Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma.
OBJECTIVE
To assess surgical staging with systematic lymphadenectomy (LND) and adjuvant therapy in patients with stage I uterine papillary serous carcinoma (UPSC).


METHODS
A single-institution, retrospective review was conducted of all surgically treated patients with primary UPSC between 1982 and 2005.


RESULTS
42 patients (IA=15, IB=21, IC=6) were stage I. 81% (n=34) underwent LND (median 40 nodes), 69% omentectomy, and 45% peritoneal biopsies. Median follow-up was 39 months. The 5-year overall survival (OS) and progression free survival (PFS) rates were 85% and 78%. The substage 5-year OS was: IA 100%, IB 89%, IC 60%. No lymphatic recurrences (LR) were observed in 34 patients who had LND compared to 1 LR in 8 who did not undergo LND (p=NS). No recurrences were detected among the 15 patients with stage IA UPSC, irrespective of post-operative therapy. None of the 20 IB and IC patients who received radiation therapy (RT) had vaginal recurrences (VR) compared to 2 of the 7 (29%) who did not receive RT (p=0.02). A systematic LND (>20 lymph nodes) was performed in 19 stage IB and IC patients. No hematological or peritoneal recurrence (HPR) was detected in the 6 patients who received chemotherapy. In contrast, HPR were observed in 3 (23%) of 13 patients who did not receive chemotherapy.


CONCLUSIONS
Observation is an option for patients with stage IA UPSC confirmed by systematic LND. Patients with comprehensively staged IB and IC UPSC are candidates for chemotherapy and vaginal brachytherapy to prevent HPR and VR.
Thomas
M Bijoy
MB
Division of Gynecologic Surgery, Mayo Clinic, Rochester, MN 55905, USA.
Mariani
Andrea
A
Cliby
William A
WA
Keeney
Gary A
GA
Podratz
Karl C
KC
Dowdy
Sean C
SC
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001918:Brachytherapy / Q000379:methods; D017024:Chemotherapy, Adjuvant; D018283:Cystadenocarcinoma, Papillary / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary* / Q000601:surgery / Q000628:therapy*; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary* / Q000601:surgery / Q000628:therapy*; D005260:Female; D006801:Humans; D008197:Lymph Node Excision; D008875:Middle Aged; D009367:Neoplasm Staging; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D014594:Uterine Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D014621:Vagina